Please assess the completion status of the following clinical trial:

Trial Title: Open-label Study of Epratuzumab in Serologically-positive Systemic Lupus Erythematosus Patients With Active Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* SL0007 patients who completed through week 12 of the study or who early terminated at week 8 or later due to treatment failure~* Patients must have maintained eligibility requirements throughout their participation in SL0007~* Written informed consent signed prior to initiation of any study-specific assessments at visit 1~Exclusion Criteria:~* Patients may not receive any live vaccination within 2 weeks prior to visit 1 or during the course of the study~* Active severe SLE disease activity which involves the CNS system (defined by BILAG neurologic A level activity) including transverse myelitis, psychosis and seizures~* Active severe SLE disease activity which involves the Renal system (defined by BILAG renal level A activity or Grade III or higher WHO nephritis) or serum creatinine \>2.5mg/dL or clinically significant serum creatinine increase within the prior 4 weeks or proteinuria \>3.5gm/day~* Patients with a history of anti-phospholipid antibody syndrome AND Use of oral anticoagulants or anti-platelet treatment~* Patients with a history of chronic infection, recent significant infection, or any current sign of symptom that may indicate an infection.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- EMAB (Type: EXPERIMENTAL): 1200 mg epratuzumab given in 2 doses every other week in 12 week treatment cycles.

Based on this trial design, predict the completion outcome and termination type (if applicable).